These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7652497)

  • 21. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of a new carbapenem, panipenem/betamipron.
    Shimada J; Kawahara Y
    Drugs Exp Clin Res; 1994; 20(6):241-5. PubMed ID: 7758396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
    Goldstein SL; Murry DJ; May S; Aleksic A; Sowinski KM; Blaney S
    Pediatr Nephrol; 2001 Dec; 16(12):1015-8. PubMed ID: 11793091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
    Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
    Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
    Leroy A; Fillastre JP; Borsa-Lebas F; Etienne I; Humbert G
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2794-8. PubMed ID: 1482147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
    Thalhammer F; Hörl WH
    Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
    Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of meropenem in subjects with renal insufficiency.
    Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
    Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Meropenem: pharmacologic advantages of clinical interest].
    Domínguez-Gil Hurlé A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():32-7. PubMed ID: 9410067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function.
    Koeppe P; Höffler D; Fitzen B
    Arzneimittelforschung; 1997 Nov; 47(11):1250-6. PubMed ID: 9428983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I.
    Fukasawa M; Sumita Y; Harabe ET; Tanio T; Nouda H; Kohzuki T; Okuda T; Matsumura H; Sunagawa M
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1577-9. PubMed ID: 1510457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic.
    Nakashima M; Uematsu T; Ueno K; Nagashima S; Inaba H; Nakano M; Kosuge K; Kitamura M; Sasaki T
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):70-6. PubMed ID: 8458679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men.
    Ljungberg B; Nilsson-Ehle I
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1437-40. PubMed ID: 1510440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
    Teitelbaum AM; Meissner A; Harding RA; Wong CA; Aldrich CC; Remmel RP
    Bioorg Med Chem; 2013 Sep; 21(17):5605-17. PubMed ID: 23845282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem pharmacokinetics and penetration into an inflammatory exudate.
    Wise R; Logan M; Cooper M; Ashby JP; Andrews JM
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1515-7. PubMed ID: 2221860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
    Waller ES
    J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the structures of meropenem(SM-7338) and it's primary metabolite.
    Takeuchi Y; Inoue T; Sunagawa M
    J Antibiot (Tokyo); 1993 May; 46(5):827-32. PubMed ID: 8514637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics of metronidazole and its metabolites in critically ill patients.
    Plaisance KI; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 1988 Feb; 21(2):195-200. PubMed ID: 3360682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem and continuous renal replacement.
    Thalhammer F
    Crit Care Med; 2001 Aug; 29(8):1653-4. PubMed ID: 11505159
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.
    Sundelof JG; Hajdu R; Gill CJ; Thompson R; Rosen H; Kropp H
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1743-8. PubMed ID: 9257753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.